The Janus kinase (JAK) family of non-receptor tyrosine kinases are the intracellular signal transducers used by more than fifty cytokines, growth factors, and interferons to drive gene transcription through the signal transducer and activator of transcription (STAT) pathway. Because so many pro-inflammatory cytokines converge on this pathway, JAK inhibitors can suppress multiple upstream signals simultaneously, which accounts for their broad clinical efficacy across inflammatory diseases and their class-wide safety profile.
The JAK Family: Four Isoforms with Distinct Receptor Partnerships. The JAK (Janus kinase) family consists of four members: JAK1 (Janus kinase 1), JAK2 (Janus kinase 2), JAK3 (Janus kinase 3), and TYK2 (tyrosine kinase 2). Each isoform preferentially associates with specific cytokine receptor subunits, creating distinct signaling units that transduce signals from particular cytokine families. JAK1 is ubiquitously expressed and pairs with multiple receptor chains, particularly the common gamma chain (gamma-c chain, CD132) of Type I cytokine receptors and the gp130 chain shared by interleukin-6 (IL-6) family receptors; JAK1 also associates with receptors for Type I and Type II interferons. JAK2 is broadly expressed and pairs with erythropoietin (EPO), thrombopoietin (TPO), growth hormone, prolactin, and granulocyte-colony stimulating factor (G-CSF) receptors, accounting for its critical role in hematopoiesis; JAK2 also pairs with interferon-gamma (IFN-gamma) and interleukin-12 (IL-12) receptors. JAK3 has restricted expression on hematopoietic cells and pairs exclusively with the gamma-c chain (CD132), meaning JAK3 is active only for cytokines that signal through this common subunit: interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-7 (IL-7), interleukin-9 (IL-9), interleukin-15 (IL-15), and interleukin-21 (IL-21). TYK2 pairs with the receptors for IL-12, interleukin-23 (IL-23), Type I interferons, and interleukin-10 (IL-10). These receptor-JAK pairings explain both the efficacy and toxicity profiles of differently selective inhibitors.1
The JAK-STAT Signaling Cascade. The canonical JAK-STAT (Janus kinase-signal transducer and activator of transcription) pathway proceeds through a sequence of four steps. First, cytokine binding induces dimerization or conformational change of the receptor subunits, bringing the constitutively associated JAK molecules into proximity. Second, the JAK molecules transactivate each other by phosphorylating tyrosine residues in the activation loop of the partner JAK (a process called trans-phosphorylation), activating their kinase domains. Third, the activated JAK kinases phosphorylate tyrosine residues on the intracellular portion of the cytokine receptor, creating docking sites for specific STAT proteins. Fourth, the recruited STAT proteins are phosphorylated by JAK, causing them to dissociate from the receptor, homodimerize or heterodimerize, translocate to the nucleus, and bind specific promoter sequences called interferon-stimulated response elements (ISREs) or gamma-activated sequence (GAS) elements to drive transcription of target genes. Seven isoforms are activated: STAT1 (signal transducer and activator of transcription 1) through STAT4 (STAT protein 4), STAT5a, STAT5b, and STAT6 (STAT protein 6) by different cytokine-JAK combinations, providing specificity within the broadly shared signaling framework.1
Therapeutic Rationale for JAK Inhibition. The therapeutic rationale for JAK inhibition in inflammatory disease rests on several converging observations. In rheumatoid arthritis (RA), the synovial cytokine environment is dominated by IL-6 (JAK1/2), IL-15 (JAK1/3), IL-2 (JAK1/3), and IFN-gamma (JAK1/2), all of which drive T-cell and macrophage activation, synovial fibroblast proliferation, osteoclast activation, and perpetuation of the inflammatory cycle. A single JAK1 or JAK1/2 inhibitor can simultaneously reduce signaling from multiple of these drivers in a way that no individual cytokine-targeted antibody can achieve. The same principle applies in inflammatory bowel disease (IBD), where IL-12 (JAK2/TYK2), IL-23 (JAK2/TYK2), and multiple other cytokines drive mucosal inflammation; in atopic dermatitis (AD), where IL-4 (JAK1), IL-13 (JAK1), interleukin-31 (IL-31; JAK1), and thymic stromal lymphopoietin (TSLP) drive itch, barrier dysfunction, and type 2 inflammation; and in myelofibrosis, where JAK2 gain-of-function mutations (particularly JAK2 V617F) drive constitutive JAK2 signaling independently of ligand binding. The small-molecule oral delivery, rapid onset of action (days rather than weeks), and reversibility of effect upon discontinuation are additional advantages over biologic therapies in certain clinical scenarios.1
Isoform Selectivity: Rationale and Limitations. The four JAK isoforms are structurally similar, sharing a catalytic kinase domain (JH1), a pseudokinase domain (JH2), and an SH2 (Src homology 2) domain. Because the adenosine triphosphate (ATP)-binding pockets of all four isoforms are highly conserved, achieving true isoform selectivity is pharmacologically challenging; all approved JAK inhibitors inhibit more than one isoform to varying degrees at therapeutic concentrations, and their described selectivity profiles are based on biochemical assays at specific drug concentrations that may not fully reflect intracellular drug concentrations in inflamed tissues. Tofacitinib was the first approved JAK inhibitor (2012) and inhibits JAK1 and JAK3 preferentially; baricitinib preferentially inhibits JAK1 and JAK2; upadacitinib preferentially inhibits JAK1; abrocitinib preferentially inhibits JAK1; filgotinib preferentially inhibits JAK1. The clinical consequence of JAK2 inhibition at therapeutic doses is suppression of EPO signaling (causing anemia) and G-CSF signaling (causing neutropenia), which are dose-limiting toxicities managed by monitoring and dose adjustment. JAK3 inhibition (more prominent with tofacitinib) may account for some of the immunosuppressive effects mediated through gamma-c-dependent cytokines.1
JAK1: IL-2, IL-4, IL-6, IL-7, IL-9, IL-10, IL-13, IL-15, IL-21, IFN-alpha/beta (Type I), IFN-gamma (Type II). JAK2: EPO, TPO, growth hormone, prolactin, G-CSF, GM-CSF, IFN-gamma, IL-3, IL-5, IL-12. JAK3: gamma-c (CD132) chain exclusively → IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 (always paired with JAK1). TYK2: IL-12, IL-23, Type I IFNs, IL-10. Consequence of JAK2 inhibition: anemia (EPO ↓), neutropenia (G-CSF ↓), thrombocytopenia (TPO ↓); monitor CBC. JAK3 inhibition mimics common gamma-chain immunodeficiency → profound T-cell functional suppression.
Five Janus kinase (JAK) inhibitors are currently approved in the United States and European Union for inflammatory diseases, with varying isoform selectivity profiles, indication sets, and evidence bases. All are orally administered small molecules that rapidly achieve therapeutic concentrations, providing an oral alternative to subcutaneous or intravenous biologics in indications where patient preference, injection barrier, or access issues make biologics suboptimal.
Tofacitinib: Inhibitor of JAK1 (Janus Kinase 1) and JAK3 (Janus Kinase 3). Tofacitinib was the first oral JAK inhibitor approved by the US Food and Drug Administration (FDA), receiving approval for rheumatoid arthritis (RA) in 2012 followed by psoriatic arthritis (PsA), ankylosing spondylitis (AS), ulcerative colitis (UC), and polyarticular juvenile idiopathic arthritis (pJIA). Tofacitinib inhibits JAK1 (Janus kinase 1) and JAK3 (Janus kinase 3) at clinically relevant concentrations with some inhibition of JAK2 (Janus kinase 2) at higher doses. The standard dose for RA and PsA is 5 mg twice daily; an extended-release formulation (11 mg once daily) is also approved for RA. For ulcerative colitis, a higher induction dose of 10 mg twice daily for 8 weeks is used, followed by 5 mg twice daily for maintenance in patients who have achieved response; in patients with moderate-to-severe UC without prior tumor necrosis factor (TNF) inhibitor exposure who have an adequate response to induction, 10 mg twice daily maintenance can also be used. The efficacy of tofacitinib in RA is comparable to that of biologic DMARDs (disease-modifying antirheumatic drugs), with ACR20 (American College of Rheumatology 20% improvement) response rates of 50 to 60% at 3 months and radiographic progression inhibition comparable to adalimumab in head-to-head studies.11
Baricitinib: Combined JAK1 and JAK2 Inhibitor with Alopecia Areata Approval. Baricitinib preferentially inhibits JAK1 and JAK2, with lower activity at JAK3 (Janus kinase 3) and TYK2 (tyrosine kinase 2). It is approved for RA, AS, alopecia areata (AA), and atopic dermatitis (AD). The RA dose is 2 mg once daily (with 4 mg once daily for patients with inadequate response to one or more DMARDs); the 4 mg dose carries a stronger safety signal and is generally reserved for patients with highly active disease and adequate risk-benefit assessment. In alopecia areata, baricitinib became the first FDA-approved systemic treatment (4 mg once daily), demonstrating SALT (Severity of Alopecia Tool) score improvements in 30 to 35% of patients at week 36, with near-complete or complete scalp hair regrowth in a meaningful proportion. The mechanism in alopecia areata involves blockade of JAK1 (Janus kinase 1)/JAK2 (Janus kinase 2)-mediated interferon-gamma (IFN-gamma) and interleukin-15 (IL-15) signaling, which drives autoimmune destruction of hair follicles by collapsing the follicular immune privilege that normally shields them from cytotoxic T-cell recognition. Baricitinib also received Emergency Use Authorization during the coronavirus disease 2019 (COVID-19) pandemic for treatment of severe COVID-19-related inflammation in hospitalized patients, based on its ability to reduce interferon-driven cytokine storm.2
Upadacitinib: Selective JAK1 Inhibitor with Broad Indication Set. Upadacitinib is the most selective approved JAK1 inhibitor currently on the market, with approximately 60-fold selectivity for JAK1 over JAK2 in biochemical assays, designed with the goal of reducing JAK2-mediated hematological toxicity (anemia, neutropenia) while maintaining JAK1-driven anti-inflammatory efficacy. It is approved for RA (15 mg once daily), PsA (15 mg once daily), AS (15 mg once daily), non-radiographic axial spondyloarthropathy (15 mg once daily), atopic dermatitis (15 mg once daily for moderate-to-severe AD; 30 mg once daily for patients with inadequate response to other agents), Crohn's disease (45 mg once daily induction for 12 weeks, then 15 or 30 mg once daily maintenance), and ulcerative colitis (45 mg once daily induction for 8 weeks, then 15 or 30 mg once daily maintenance). In head-to-head trials in RA (SELECT-COMPARE), upadacitinib 15 mg once daily was superior to adalimumab on ACR50 (American College of Rheumatology 50% improvement) response rates at 26 weeks, representing a landmark result demonstrating that a selective JAK1 inhibitor could outperform a TNF inhibitor in a randomized head-to-head trial in RA.23
Abrocitinib and Filgotinib: Dermatology and Rheumatology JAK1 Inhibitors. Abrocitinib is a selective JAK1 inhibitor approved specifically for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older, at doses of 100 mg and 200 mg once daily. Its high selectivity for JAK1 is intended to maximize blockade of the JAK1-dependent cytokines driving AD (IL-4, IL-13, IL-31, TSLP) while minimizing hematological effects from JAK2 or JAK3 inhibition; nonetheless, platelet count decreases occur with abrocitinib (particularly at 200 mg) and platelet monitoring is recommended during the first 4 weeks. In phase 3 trials, abrocitinib 200 mg demonstrated rapid itch relief (the Pruritus Numeric Rating Scale (NRS), a validated numeric rating scale for itch, improved within days), which is faster than dupilumab and reflects the direct suppression of JAK1-dependent IL-31 signaling. Filgotinib is a selective JAK1 inhibitor approved in the European Union for RA and UC; it has not received FDA approval due to a clinical hold related to concerns about male fertility based on high-dose animal studies, though subsequent human male fertility studies in RA patients have not demonstrated impairment at therapeutic doses.11
RA: All five (tofacitinib, baricitinib, upadacitinib, filgotinib [EU only]; after methotrexate failure or combination with MTX). PsA / AS / nr-axSpA: Tofacitinib, upadacitinib. Atopic dermatitis: Baricitinib, upadacitinib, abrocitinib. Alopecia areata: Baricitinib (only approved systemic therapy). Ulcerative colitis: Tofacitinib, upadacitinib, filgotinib [EU]. Crohn's disease: Upadacitinib. COVID-19 (hospitalized): Baricitinib (Emergency Use Authorization). JAK inhibitors are oral alternatives to biologic DMARDs; avoid in patients age ≥65, current/past smokers, cardiovascular risk, or prior malignancy based on ORAL Surveillance data.
The safety profile of Janus kinase (JAK) inhibitors as a class was substantially redefined by the ORAL (Oral Rheumatoid Arthritis triaLs) Surveillance trial, a post-marketing required safety trial of tofacitinib in high-risk rheumatoid arthritis (RA) patients. The results prompted FDA-mandated class-wide black box warnings for all approved JAK inhibitors, restricting their use in certain high-risk populations and requiring them to be used only after tumor necrosis factor (TNF) inhibitor failure in indications where a TNF inhibitor alternative exists. Understanding this evidence base is essential for risk-stratified prescribing of the entire drug class.
The ORAL Surveillance Trial: Design and Findings. ORAL Surveillance was a post-marketing safety study mandated by the FDA as a condition of tofacitinib approval, conducted in patients with active RA who were 50 years of age or older and had at least one additional cardiovascular risk factor (defined as a history of heart attack, stroke, or high cardiovascular risk by other criteria). Patients were randomized to tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, or a TNF inhibitor (adalimumab or etanercept at standard doses). The pre-specified non-inferiority margin required that tofacitinib not exceed the cardiovascular event rate of the TNF inhibitor comparator by more than 50%. Results published in the New England Journal of Medicine in 2022 showed that tofacitinib failed the non-inferiority test for major adverse cardiovascular events (MACE), defined as cardiovascular death, non-fatal myocardial infarction (MI), or non-fatal stroke: incidence rate of MACE was 3.4% per year for tofacitinib versus 2.5% for TNF inhibitor. Additionally, tofacitinib was associated with higher rates of cancer (hazard ratio (HR) approximately 1.48, driven by non-melanoma skin cancer and lung cancer), venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE), and serious infections compared to TNF inhibitors. The 10 mg twice-daily dose showed numerically higher event rates than 5 mg twice daily for most outcomes.4
FDA Regulatory Response and Black Box Warning. In response to ORAL Surveillance, the FDA in 2021 required a class-wide black box warning for all approved JAK inhibitors (tofacitinib, baricitinib, upadacitinib) covering: (1) serious infections, including opportunistic infections, reactivation of herpes zoster (HZ), and tuberculosis (TB); (2) mortality (all-cause mortality was numerically higher with tofacitinib than TNF inhibitor, though not statistically significant for the primary endpoint); (3) malignancy including lymphoma; (4) major adverse cardiovascular events; and (5) thrombosis including DVT and PE. The FDA also restricted JAK inhibitors to use only in patients who have had an inadequate response or intolerance to one or more TNF inhibitors in most rheumatic indications (RA, PsA, AS), with warnings to avoid use in patients who are 65 years of age or older, current or past smokers, or have a history of atherosclerotic cardiovascular disease, other cardiovascular risk factors, or malignancy whenever possible. Dermatology indications (AD, alopecia areata) were not subject to the TNF inhibitor prior-failure restriction but carry the same black box warnings.45
Herpes Zoster Reactivation: The Most Common Infectious Complication. Among all infectious adverse effects of JAK inhibitors, herpes zoster (HZ) reactivation is by far the most common, occurring at a rate approximately 2 to 4 times higher than with biologic DMARDs across all JAK inhibitors and indications. The pathophysiology involves JAK1 (Janus kinase 1)-dependent suppression of type I interferon signaling (critical for control of varicella-zoster virus reactivation) and JAK1/2 (Janus kinase 1/2)-dependent suppression of IFN-gamma (interferon-gamma, critical for cytotoxic T-cell (cluster of differentiation 8 positive, CD8+) surveillance of latent varicella-zoster virus in dorsal root ganglia). Rates of HZ in JAK inhibitor-treated patients range from 3 to 8 events per 100 patient-years in RA populations, compared to approximately 1 to 2 events per 100 patient-years with TNF inhibitors. HZ manifests predominantly as dermatomal shingles, but disseminated or visceral HZ (HZ opthalmicus, HZ meningitis) occurs more frequently than in the general population. The recombinant zoster vaccine Shingrix (two-dose series, 2 to 6 months apart) is strongly recommended before initiating any JAK inhibitor in age-eligible patients (age 50 and older); because Shingrix is an inactivated subunit vaccine (not a live vaccine), it can also be administered during JAK inhibitor therapy, though immunogenicity may be somewhat reduced.5
Venous Thromboembolism and Cardiovascular Risk Stratification. Elevated rates of VTE, specifically DVT and PE, were observed with tofacitinib (particularly at 10 mg twice daily) in ORAL Surveillance and in post-marketing reports. The mechanism of JAK inhibitor-associated thrombosis is not fully understood but may involve JAK2 (Janus kinase 2)-mediated platelet activation pathways and effects on endothelial function. VTE incidence rates in JAK inhibitor-treated RA patients in clinical trials and registries are approximately 0.5 to 1.5 events per 100 patient-years, which may be higher than background RA rates. All JAK inhibitors carry a class-wide VTE warning. Patients with pre-existing VTE risk factors (prior VTE, obesity, immobility, thrombophilia, use of oral contraceptives) should be assessed carefully before initiating JAK inhibitor therapy, and JAK inhibitors should generally be avoided in patients with prior VTE or high VTE risk if alternative therapies are available. Regarding MACE, the risk was numerically higher across multiple JAK inhibitor trials compared to TNF inhibitors, and all JAK inhibitor labels now recommend using these agents with caution in patients with established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors.45
Serious infections: Bacterial, mycobacterial, invasive fungal, viral (especially herpes zoster), and other opportunistic infections. Screen for TB before initiation; avoid in active serious infection. Mortality: All-cause mortality numerically higher vs. TNF inhibitors in ORAL Surveillance. Malignancy: Lymphoma and other cancers; higher rate of non-melanoma skin cancer; lung cancer risk elevated in smokers. MACE: MI, stroke, CV death; avoid in patients with established CV disease or multiple CV risk factors when alternatives exist. Thrombosis: DVT, PE; avoid in patients with prior VTE or high VTE risk. Restrict use: Use after TNF inhibitor failure in RA, PsA, AS; avoid in age ≥65, smokers, prior CV disease, prior malignancy when alternatives exist. Shingrix strongly recommended before initiation for all age-eligible patients.
Beyond Janus kinase (JAK) inhibitors, several other classes of targeted small molecules have entered clinical use in inflammatory diseases. These agents share the advantage of oral administration but differ from JAK inhibitors in their mechanisms of action, safety profiles, and regulatory status. Unlike JAK inhibitors, none of the agents in this section carry the ORAL (Oral Rheumatoid Arthritis triaLs) Surveillance-derived black box warnings, reflecting their distinct mechanistic and safety profiles.
Apremilast: Phosphodiesterase 4 Inhibitor. Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), the predominant phosphodiesterase isoenzyme in immune cells. PDE4 catalyzes the hydrolysis of cyclic adenosine monophosphate (cAMP) to 5-AMP; by inhibiting PDE4, apremilast increases intracellular cAMP levels, activating protein kinase A (PKA) and downstream signaling that suppresses the production of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-17 (IL-17), interleukin-23 (IL-23), and interferon-gamma, while increasing the anti-inflammatory cytokine interleukin-10 (IL-10). The mechanism is thus anti-inflammatory but not specifically immunosuppressive: apremilast does not cause the degree of immune suppression associated with JAK inhibitors or biologics. Apremilast is approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. In psoriasis, efficacy is more modest than biologics (Psoriasis Area and Severity Index 75 (PASI 75) response rates of approximately 30 to 40% vs. 60 to 80% for biologic agents), but apremilast is used as an intermediate-step option when topicals have failed and biologics are contraindicated or declined; it is also used in patients with mild-to-moderate psoriasis not requiring biologic therapy.
Apremilast in Psoriatic Arthritis. In psoriatic arthritis (PsA), apremilast reduces tender and swollen joint counts, skin disease, and dactylitis, with efficacy similar to traditional disease-modifying antirheumatic drugs (DMARDs) but below that of TNF inhibitors. The most common adverse effects are gastrointestinal (GI): nausea, diarrhea, and headache, occurring in up to 30% of patients in the first 4 to 6 weeks and typically improving with continued therapy.6
Apremilast Tolerability and Safety Advantages. A gradual titration schedule over 5 days reduces gastrointestinal (GI) adverse effects at initiation and should be used routinely. Apremilast is associated with modest weight loss (approximately 1 to 2 kg) and, in contrast to JAK inhibitors and biologics, is free of significant infection, malignancy, and cardiovascular risks; it does not carry the class-wide black box warnings of the JAK inhibitor class. These tolerability characteristics make apremilast suitable for patients with comorbidities that preclude JAK inhibitors or biologics, including elderly patients and those with cardiovascular risk factors or prior malignancy.6
S1P Receptor Modulators: Ozanimod and Siponimod. Sphingosine 1-phosphate (S1P) is a bioactive lipid mediator that regulates lymphocyte trafficking between lymphoid organs and the peripheral circulation. Lymphocytes express S1P receptors (S1P1 through S1P5), and high plasma S1P concentrations relative to lymph node S1P concentrations create a gradient that drives lymphocyte egress from lymph nodes into the bloodstream; when S1P1 is engaged, lymphocytes exit lymph nodes and enter circulation. S1P receptor modulators are functional antagonists that cause internalization and downregulation of S1P1 on lymphocyte surfaces, effectively trapping mature lymphocytes within lymph nodes and Peyer's patches (intestinal lymphoid tissue) and reducing their trafficking to inflamed tissues. The resulting peripheral lymphopenia is dose-dependent and reversible upon drug discontinuation. Ozanimod is a selective S1P1 and S1P5 modulator approved for relapsing multiple sclerosis (MS) and moderate-to-severe ulcerative colitis (UC). In UC (ulcerative colitis), ozanimod reduces gut trafficking of activated lymphocytes, with induction response rates of approximately 48% and remission rates of approximately 18% in the True North trial. Siponimod is a selective S1P1 and S1P5 modulator approved for secondary progressive MS; it is not approved for inflammatory bowel disease (IBD).7
S1P Modulator Safety Profile. The distinctive safety profile of S1P modulators requires awareness of several class-specific effects. First-dose bradycardia and atrioventricular (AV) block can occur, requiring cardiac monitoring for at least 6 hours after the first dose in at-risk patients (those with existing cardiac conduction abnormalities, antiarrhythmic use, or baseline bradycardia). Macular edema requires an ophthalmic examination before initiation and in any patient who develops blurred vision. Elevated liver transaminases occur in a minority of patients and require monitoring. Herpes zoster reactivation risk is increased, and Shingrix vaccination before initiation is recommended. Coadministration with monoamine oxidase (MAO) inhibitors is contraindicated due to risk of serotonin syndrome.7
Deucravacitinib: TYK2 (Tyrosine Kinase 2) Allosteric Inhibitor. Deucravacitinib represents a mechanistically distinct approach to JAK family inhibition. Rather than competing with adenosine triphosphate (ATP) at the catalytic JH1 (JAK homology 1) kinase domain as conventional JAK inhibitors do, deucravacitinib is an allosteric inhibitor that binds the regulatory pseudokinase domain (JH2) of TYK2, stabilizing it in an autoinhibited conformation that suppresses kinase activity without occupying the ATP-binding site. This allosteric mechanism confers exceptional isoform selectivity: deucravacitinib has greater than 2,000-fold selectivity for TYK2 over JAK1 (Janus kinase 1), JAK2 (Janus kinase 2), and JAK3 (Janus kinase 3) in enzymatic assays, because the JH2 domains of the four JAK isoforms are substantially less conserved than their JH1 kinase domains.8
Deucravacitinib: Clinical Efficacy and Positioning. By selectively inhibiting TYK2, deucravacitinib suppresses signaling by IL-12 (interleukin-12, drives Th1 differentiation), IL-23 (interleukin-23, drives Th17 differentiation), and Type I interferons, without appreciably affecting JAK1-dependent or JAK2-dependent cytokine signaling. The clinical consequence is selective suppression of the interleukin-12 (IL-12)/interleukin-23 (IL-23)/Th17 axis driving psoriatic inflammation, with minimal hematological toxicity and without the cardiovascular, thrombotic, or malignancy signals of non-selective JAK inhibitors. Deucravacitinib is approved for moderate-to-severe plaque psoriasis; in the POETYK (Psoriasis Outcomes and Endpoints Trial of TYK2 inhibitor) phase 3 trials designated PSO-1 (Psoriasis Study 1) and PSO-2 (Psoriasis Study 2), deucravacitinib achieved PASI 75 in approximately 58 to 62% of patients at week 16, significantly superior to apremilast (approximately 31 to 38%) in head-to-head comparison, without the class-wide black box warnings of JAK inhibitors.8
Apremilast: Intermediate-step therapy in psoriasis and PsA; preferred when biologics or JAK inhibitors are contraindicated; GI intolerance main limiting factor; no immunosuppression. Ozanimod: UC when biologics have failed; requires first-dose cardiac monitoring; contraindicated with certain antiarrhythmics. Deucravacitinib: Plaque psoriasis; no JAK inhibitor black box warnings; superior to apremilast; positioned between apremilast and biologics or as alternative to IL-17/IL-23 biologics; no mandatory TNF inhibitor prior failure requirement.
Inflammatory bowel disease (IBD) has seen a transformation in its pharmacological management over the past decade, with the addition of gut-selective biologics and multiple small-molecule options to the established tumor necrosis factor (TNF) inhibitor and immunomodulator backbone. The expanding treatment armamentarium requires clinicians to understand the distinct mechanisms, onset profiles, and evidence bases of each agent to position them appropriately in patient-specific treatment algorithms.
Vedolizumab: Gut-Selective Anti-Integrin Therapy. Vedolizumab is a humanized IgG1 monoclonal antibody directed against the alpha-4/beta-7 (integrin alpha-4 beta-7, also written as ITGA4/ITGB7) integrin heterodimer expressed on lymphocytes, which mediates their homing to the gut mucosa by binding mucosal addressin cell adhesion molecule 1 (MAdCAM-1) expressed on gut endothelium. By blocking alpha-4/beta-7 integrin, vedolizumab selectively prevents the trafficking of activated lymphocytes into the gut lamina propria without substantially affecting systemic lymphocyte trafficking (in contrast to natalizumab, which blocks alpha-4 integrin at all sites including the central nervous system and carries a risk of progressive multifocal leukoencephalopathy (PML)). This gut-selective mechanism results in a favorable systemic safety profile: vedolizumab is not associated with meaningful systemic immunosuppression, does not require tuberculosis (TB) screening in the same manner as TNF inhibitors, and does not carry signals for increased malignancy, serious systemic infections, or cardiovascular events.9
Vedolizumab Onset and Positioning. The trade-off of gut-selective mechanism is a slower onset of action than TNF inhibitors, with maximal benefit often not apparent until 12 to 14 weeks, reflecting the time required for gradual reduction in gut mucosal lymphocyte density after blocking new lymphocyte recruitment. Vedolizumab is approved for moderate-to-severe ulcerative colitis (UC) and Crohn's disease, and is a preferred first-line biologic for patients with UC who have safety concerns with TNF inhibitors (older patients, malignancy history, prior serious infections) due to its gut-selective, systemically safe profile.9
Upadacitinib in IBD: Induction and Maintenance. Upadacitinib has the broadest IBD (inflammatory bowel disease) indication among Janus kinase (JAK) inhibitors, being approved for both Crohn's disease and ulcerative colitis. In UC, upadacitinib demonstrated superiority over placebo for clinical remission (using the adapted Mayo Clinic score) in the U-ACHIEVE and U-ACCOMPLISH trials, with induction remission rates of approximately 26 to 34% at 8 weeks versus 5 to 9% for placebo, and maintenance remission at 44 weeks of approximately 40 to 52% versus 13 to 15% for placebo. In Crohn's disease, the U-EXCEED and U-EXCEL trials showed clinical remission rates of approximately 39 to 49% at 12 weeks induction versus 14 to 22% for placebo. The approved induction dose for both UC and Crohn's disease is 45 mg once daily, reflecting the need for higher JAK1 (Janus kinase 1) inhibition to achieve mucosal healing in IBD compared to synovial inflammation in rheumatoid arthritis (RA). The maintenance dose is 15 to 30 mg once daily. As a JAK inhibitor, upadacitinib carries the class-wide black box warning for IBD indications, though the absolute risk of the major safety signals in the IBD population (which tends to be younger with fewer cardiovascular risk factors than RA trial populations) may differ from the ORAL (Oral Rheumatoid Arthritis triaLs) Surveillance-derived estimates.4
Treatment Sequencing in UC: Positioning the Agents. Current guidelines for moderate-to-severe UC generally position TNF inhibitors (infliximab, adalimumab, golimumab) as first-line biologic therapy; vedolizumab as an alternative first-line biologic particularly for patients with safety concerns about systemic immunosuppression; and upadacitinib, tofacitinib (5 to 10 mg twice daily), and ozanimod as options after TNF inhibitor failure or for patients who prefer oral therapy. In practice, the choice among these options is governed by: prior TNF inhibitor exposure and reason for failure (primary non-response vs. secondary loss of response); patient preference for oral vs. subcutaneous/intravenous administration; risk profile for the specific agent; urgency of response needed (tofacitinib and upadacitinib act more rapidly than vedolizumab or ozanimod); and insurance or formulary considerations. Infliximab retains a unique position for acute severe UC requiring hospitalization, where intravenous administration and rapid onset are advantageous over oral agents. The combination of a biologic with a small molecule (e.g., vedolizumab + tofacitinib) is not standard practice and is generally avoided due to additive immunosuppression and lack of controlled evidence.910
Crohn's Disease: Distinct Agent Positioning. The treatment landscape in Crohn's disease differs from UC in several important respects. Anti-TNF agents (infliximab, adalimumab, certolizumab) remain first-line biologics. Vedolizumab is approved and effective in Crohn's but with lower primary induction response rates than in UC, reflecting the different immunological drivers of Crohn's disease (more Th1-dominated in small bowel and transmural disease versus the Th2/type 2-prominent pattern of UC). Ustekinumab is another approved option with a favorable safety profile. Upadacitinib is the only approved JAK inhibitor for Crohn's disease. As discussed in the biologic module, etanercept, the TNFR2 (tumor necrosis factor receptor 2) fusion protein, is ineffective in Crohn's disease and should not be used, as discussed in the biologic module. Risankizumab is also approved for moderate-to-severe Crohn's disease as a biologic option, providing an alternative for patients with inadequate response to anti-TNF therapy or ustekinumab. The principles of combination therapy (immunomodulator with biologic) and therapeutic drug monitoring apply in Crohn's disease as in UC.910
Vedolizumab: Gut-selective (no systemic immunosuppression); slow onset (12–14 weeks to full effect); preferred for safety-conscious patients (elderly, malignancy history); no JAK black box warnings; IV q8wk or SQ q2wk. Upadacitinib / tofacitinib: Rapid onset (weeks); oral; carry JAK black box warnings (VTE, MACE, malignancy, infections); prefer after TNF inhibitor failure per label restriction; higher urgency of response situations. Ozanimod: Oral; S1P mechanism (lymphocyte sequestration in lymph nodes); approved for UC; first-dose cardiac monitoring required; slower onset than tofacitinib. Common to all: Avoid live vaccines; screen for TB (vedolizumab screening less stringent than anti-TNF); monitor for infection.
The small-molecule nature of Janus kinase (JAK) inhibitors and related targeted agents creates drug interaction profiles governed by cytochrome P450 (CYP) enzymes and drug transporters, unlike biologic drugs that are metabolized by proteolysis independently of these pathways. Ongoing laboratory monitoring is required for both safety and therapeutic optimization, and clinical positioning requires matching the right agent to the right patient based on comorbidities, prior therapy, and risk profile.
CYP-Based Drug Interactions: JAK Inhibitors. JAK inhibitors are substrates of CYP enzymes, with varying degrees of metabolism by cytochrome P450 3A4 (CYP3A4) and cytochrome P450 2C19 (CYP2C19). Tofacitinib is metabolized predominantly by CYP3A4 (approximately 70%) and CYP2C19 (approximately 30%); strong CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin) increase tofacitinib exposure substantially and may require dose reduction, while strong inducers (rifampin) dramatically reduce exposure and may require dose increase. Baricitinib is metabolized primarily by CYP3A4 and is also a substrate of the organic anion transporter 3 (OAT3) renal transporter; probenecid, an OAT3 inhibitor, markedly increases baricitinib plasma levels and is contraindicated with baricitinib. Upadacitinib is metabolized by CYP3A4; coadministration with strong CYP3A4 inducers (rifampin) reduces upadacitinib exposure by over 75%, which would compromise efficacy. Abrocitinib is metabolized by CYP2C19 and CYP2C9 (cytochrome P450 2C9) as well as CYP3A4; strong inhibitors or inducers of these enzymes affect abrocitinib levels, and dose adjustment may be needed in CYP2C19 poor metabolizers or patients receiving CYP2C19 inhibitors. Unlike biologic agents, JAK inhibitors are also affected by hepatic impairment: moderate hepatic impairment increases exposure of tofacitinib and upadacitinib, requiring dose reduction, and severe hepatic impairment is a contraindication for most agents in this class.11
CYP Interactions with Apremilast, Ozanimod, and Deucravacitinib. Apremilast is metabolized by CYP3A4 and is susceptible to clinically significant drug interactions with potent CYP3A4 inducers: rifampin reduces apremilast area under the curve (AUC) by approximately 72%, substantially reducing efficacy, and combination is contraindicated. Moderate inducers (carbamazepine, phenytoin, phenobarbital) are also expected to reduce apremilast exposure and should be used with caution. CYP3A4 inhibitors do not cause clinically significant increases in apremilast exposure. Ozanimod undergoes complex metabolism: the parent drug is metabolized by monoamine oxidase B (MAO-B) and CYP3A4 to active metabolites; coadministration with MAO inhibitors (used for depression or Parkinson's disease) is contraindicated due to risk of serotonin syndrome. Ozanimod also elevates heart rate through sympathomimetic mechanisms when combined with direct-acting sympathomimetic medications. Deucravacitinib is metabolized by CYP3A4 and undergoes minimal interactions at clinical doses; it does not inhibit or induce major CYP enzymes at therapeutic concentrations, representing an advantage over less selective JAK inhibitors for patients on complex medication regimens.11
Laboratory Monitoring for JAK Inhibitors. Standardized laboratory monitoring is required for all JAK inhibitors before and during therapy. Before initiation: complete blood count (CBC) with differential (to detect pre-existing cytopenias that increase risk of JAK inhibitor-induced hematological toxicity); comprehensive metabolic panel including creatinine and liver function tests; lipid panel (all JAK inhibitors increase low-density lipoprotein (LDL) and total cholesterol, typically by 5 to 15%, requiring statin initiation or dose adjustment in many patients); tuberculosis (TB) screening (TST or IGRA); hepatitis B virus (HBV) serology; and human immunodeficiency virus (HIV) testing in at-risk individuals. During therapy: CBC at 4 to 8 weeks then every 3 months (monitor for lymphopenia, neutropenia, anemia, thrombocytopenia); creatinine every 3 to 6 months; lipid panel at 4 to 8 weeks and annually; liver function tests as clinically indicated. JAK inhibitors are contraindicated in absolute lymphocyte count below 500 cells per microliter, absolute neutrophil count (ANC) below 1,000 cells per microliter, hemoglobin below 8 g/dL, or platelet count below 50,000 per microliter. Interruption and dose reduction thresholds are specified in each agent's prescribing information and must be followed to maintain safety margins.11
Lipid Effects of JAK Inhibitors and Cardiovascular Management. All JAK inhibitors increase serum lipid levels, an effect that appears within the first 4 to 8 weeks of treatment and is believed to reflect restoration of JAK (Janus kinase)-STAT (signal transducer and activator of transcription)-mediated hepatic lipid metabolism regulation (suppressed during active inflammation) rather than a direct atherogenic mechanism; however, the net cardiovascular impact of these lipid increases in the context of the major adverse cardiovascular events (MACE) findings from ORAL (Oral Rheumatoid Arthritis triaLs) Surveillance is clinically meaningful. LDL cholesterol increases by approximately 10 to 20% with JAK1 (Janus kinase 1)/JAK2 (Janus kinase 2) inhibitors, with larger increases at higher doses. Statin therapy should be initiated or optimized in patients with elevated LDL (low-density lipoprotein) or established cardiovascular risk when starting JAK inhibitor therapy.12 In clinical practice, the decision to initiate or escalate a statin concurrent with JAK inhibitor therapy should be guided by the patient's overall cardiovascular risk profile using established risk calculators (10-year atherosclerotic cardiovascular disease, ASCVD, risk score), with a low threshold for statin initiation given the additive cardiovascular risk signals of JAK inhibitors in the ORAL Surveillance population.412
Prefer oral small molecule (JAK inhibitor or other): Patient declines injections; needle phobia; poor venous access limiting IV biologics; need for rapid onset (hospitalized UC); preference for oral therapy. Prefer biologic: Age ≥65 or high cardiovascular risk (JAK inhibitor safety concern); personal or family history of malignancy; prior or current VTE; heavy smoker; patient who is pregnant or planning pregnancy (certolizumab most data). Prefer vedolizumab (biologic) over JAK inhibitor: IBD patient with prior malignancy, recurrent infections, older age, or cardiovascular risk factors. Deucravacitinib niche: Psoriasis without the JAK inhibitor liability; oral alternative to IL-17/IL-23 inhibitors; no mandatory prior-TNF failure requirement; selective TYK2 mechanism avoids hematological and CV risks.
O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311-328.
doi:10.1146/annurev-med-051113-024537Smolen JS, Genovese MC, Takeuchi T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019;46(1):7-18.
doi:10.3899/jrheum.171361Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788-1800.
doi:10.1002/art.41032Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326.
doi:10.1056/NEJMoa2109927Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-243.
doi:10.1038/nrrheum.2017.23Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842-855.
doi:10.1111/j.1476-5381.2009.00559.xSandborn WJ, Feagan BG, D'Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280-1291.
doi:10.1056/NEJMoa2033617Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29-39.
doi:10.1016/j.jaad.2022.07.002Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.
doi:10.1056/NEJMoa1215734Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-1736.
doi:10.1056/NEJMoa1606910Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-862.
doi:10.1038/nrd.2017.201Burmester GR, Winthrop K, Bhatt DL, et al. Cardiovascular safety of tofacitinib, baricitinib, and upadacitinib in patients with rheumatoid arthritis. Ann Rheum Dis. 2023;82(5):622-631.
doi:10.1136/ard-2022-222841